Skip to main content
Clinical Trials/NL-OMON51129
NL-OMON51129CompletedNot Applicable

Cardionomic Cardiac Pulmonary Nerve Stimulation Pilot Study - CPNS Pilot Study

Cardionomic Inc0 sites10 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Subjects must meet all the following inclusion criteria to be eligible to
  • participate in this study:
  • 1. At least 18 years of age, or older if required by local law
  • 2. Admitted to the hospital with a principal diagnosis of acute decompensated
  • heart failure.
  • 3. BMI adjusted BNP >= 500 pg/mL or NT-pro-BNP >= 2000 pg/mL; 4% reduction in
  • BNP/NT-proBNP for every increase of 1 kg/m2 in BMI above a reference of 20kg/m2
  • (Refer to Appendix B: BNP/NT-proBNP corrected for BMI)
  • 4. Left ventricular ejection fraction <= 45%; documented within previous 12
  • 5. At least one sign or symptom of fluid overload
  • 6. At least one of the following:
  • o Persistent inadequate diuretic response
  • o At least one sign or symptom of low perfusion

Exclusion Criteria

  • 1. First IV treatment upon presentation in hospital to randomization is > 48
  • 2. Received an inotrope during current hospitalization or anticipated to
  • receive an inotrope in the 12 hours following enrollment
  • 3. Requires mechanical support (e.g., mechanical circulatory support,
  • ultrafiltration) or anticipated to receive mechanical support in the 12 hours
  • following enrollment
  • 4. Manually measured systolic blood pressure < 80 mmHg at screening
  • 5. Manually measured systolic blood pressure > 130 mmHg at screening
  • 6. Symptomatic hypotension
  • 7. eGFR < 25 mL/min/1.73m2
  • 8. Has an active infection
  • 9. Has an active or passive implantable device that may interfere with CPNS
  • therapy per physician discretion
  • 10. Has a cardiac resynchronization therapy (CRT) device or a pacemaker
  • 11. Has an implantable cardioverter defibrillator (ICD) and is pacemaker
  • dependent or has had a sustained VT/VF episode in the previous 90 days (a
  • subject can be enrolled if he/she meets this criterion, the physician deems it
  • appropriate to suspend therapies during hospitalization and leads have been
  • implanted for at least six months prior to the study procedure) 12. Permanent
  • or persistent atrial fibrillation with uncontrolled ventricular response
  • (ventricular rate > 125 BPM) at time of enrollment
  • 13. Unstable angina or documented myocardial infarction within last 30 days
  • 14. Prior heart transplant
  • 15. History of severe mitral or aortic stenosis or regurgitation
  • 16. History of pulmonary embolism within the last 6 months
  • 17. History of hyper-coagulation disorders
  • 18. History of more than one CABG procedure
  • 19. History of severe pulmonary hypertension (pulmonary arterial systolic
  • pressure >= 75 mmHg)
  • 20. Diagnosis of primary pulmonary hypertension
  • 21. Diagnosis of congenital heart disease
  • 22. Participating in concurrent trial unless approved by Cardionomic study
  • 23. Pregnant or childbearing age and not on reliable form of birth control
  • 24. Allergy to nickel, fentanyl, midazolam, propofol, heparin, eggs, egg
  • products, soybeans or soy products
  • 25. Unwilling or unable to provide consent
  • 26. Exclusion criteria by local law (e.g., age, prisoner, etc)

Investigators

Similar Trials